BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30464200)

  • 1. Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis.
    Gadaleta RM; Scialpi N; Peres C; Cariello M; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A
    Sci Rep; 2018 Nov; 8(1):17210. PubMed ID: 30464200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor.
    Gadaleta RM; Garcia-Irigoyen O; Cariello M; Scialpi N; Peres C; Vetrano S; Fiorino G; Danese S; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A
    EBioMedicine; 2020 Apr; 54():102719. PubMed ID: 32259714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19.
    Piglionica M; Cariello M; Moschetta A
    Curr Opin Pharmacol; 2018 Dec; 43():93-98. PubMed ID: 30223181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism.
    Cariello M; Piglionica M; Gadaleta RM; Moschetta A
    Handb Exp Pharmacol; 2019; 256():73-93. PubMed ID: 31123830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4
    Cariello M; Peres C; Zerlotin R; Porru E; Sabbà C; Roda A; Moschetta A
    Sci Rep; 2017 Sep; 7(1):11203. PubMed ID: 28894223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
    Zhou M; Luo J; Chen M; Yang H; Learned RM; DePaoli AM; Tian H; Ling L
    J Hepatol; 2017 Jun; 66(6):1182-1192. PubMed ID: 28189755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.
    Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A
    Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis.
    Byun S; Kim DH; Ryerson D; Kim YC; Sun H; Kong B; Yau P; Guo G; Xu HE; Kemper B; Kemper JK
    Nat Commun; 2018 Jul; 9(1):2590. PubMed ID: 29968724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.
    Liu Y; Chen K; Li F; Gu Z; Liu Q; He L; Shao T; Song Q; Zhu F; Zhang L; Jiang M; Zhou Y; Barve S; Zhang X; McClain CJ; Feng W
    Hepatology; 2020 Jun; 71(6):2050-2066. PubMed ID: 31571251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice.
    Ikpa PT; Doktorova M; Meijsen KF; Nieuwenhuijze NDA; Verkade HJ; Jonker JW; de Jonge HR; Bijvelds MJC
    Cell Mol Gastroenterol Hepatol; 2020; 9(1):47-60. PubMed ID: 31470114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers.
    Al-Khaifi A; Rudling M; Angelin B
    Gastroenterology; 2018 Oct; 155(4):1012-1016. PubMed ID: 29928896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.
    Appleby RN; Moghul I; Khan S; Yee M; Manousou P; Neal TD; Walters JRF
    PLoS One; 2019; 14(1):e0211348. PubMed ID: 30682184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.
    Zhou M; Learned RM; Rossi SJ; DePaoli AM; Tian H; Ling L
    Hepatology; 2016 Mar; 63(3):914-29. PubMed ID: 26418580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease.
    Wunsch E; Milkiewicz M; Wasik U; Trottier J; Kempińska-Podhorodecka A; Elias E; Barbier O; Milkiewicz P
    Sci Rep; 2015 Aug; 5():13462. PubMed ID: 26293907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol.
    Bertolini A; van de Peppel IP; Doktorova-Demmin M; Bodewes FAJA; de Jonge H; Bijvelds M; Verkade HJ; Jonker JW
    Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G404-G411. PubMed ID: 30653340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism.
    Hu X; Bonde Y; Eggertsen G; Rudling M
    J Intern Med; 2014 Jan; 275(1):27-38. PubMed ID: 24118394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling.
    Di Ciaula A; Bonfrate L; Baj J; Khalil M; Garruti G; Stellaard F; Wang HH; Wang DQ; Portincasa P
    Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho.
    Fu T; Kim YC; Byun S; Kim DH; Seok S; Suino-Powell K; Xu HE; Kemper B; Kemper JK
    Mol Endocrinol; 2016 Jan; 30(1):92-103. PubMed ID: 26505219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations.
    Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
    Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
    J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.